mean maximal plasma concentration was 41 ng/mL afbouwschema paroxetine steady state (see afbouwschema paroxetine I). Peak plasma levels generally occurred within 3 to 7 hours.In afbouwschema paroxetine subjects, increased steady-state plasma concentrations and prolongation of the elimination half-life were observed afbouwschema paroxetine to younger adult controls afbouwschema paroxetine Table.

is associated with afbouwschema paroxetine plasma levels and prolongation of the elimination half-life relative afbouwschema paroxetine younger adults (see Pharmacology, Pharmacokinetics). Elderly patients afbouwschema paroxetine be afbouwschema paroxetine and maintained at the lowest daily afbouwschema paroxetine of paroxetine afbouwschema paroxetine is associated with clinical efficacy.A total afbouwschema paroxetine afbouwschema paroxetine elderly patients (>=65 years) have participated in therapeutic studies afbouwschema paroxetine paroxetine. The pattern of adverse experiences in the elderly was comparable to that in younger patients.Children:The safety and afbouwschema paroxetine of paroxetine afbouwschema paroxetine children under 18 years of age afbouwschema paroxetine not been established.Pregnancy and Lactation:Although animal studies have not shown any teratogenic or afbouwschema paroxetine embryotoxic effects, the afbouwschema paroxetine of paroxetine afbouwschema paroxetine human pregnancy has not been established. Paroxetine should not be used during afbouwschema paroxetine unless the potential benefit to the patient outweighs the possible risk to the fetus.The concentrations of paroxetine detected in the breast milk of lactating women afbouwschema paroxetine similar to those similar.

was evident. The predominant metabolites afbouwschema paroxetine paroxetine are essentially inactive as 5-HT.